Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes

Patients’ selection is particularly important in cancer treatment. Here the authors present a proof-of-principle methodology that could be potentially important in assisting therapeutic decisions in the treatment of breast cancer patients.

Guardado en:

Detalles Bibliográficos
Autores principales:	Valeriy Domenyuk, Zoran Gatalica, Radhika Santhanam, Xixi Wei, Adam Stark, Patrick Kennedy, Brandon Toussaint, Symon Levenberg, Jie Wang, Nianqing Xiao, Richard Greil, Gabriel Rinnerthaler, Simon P. Gampenrieder, Amy B. Heimberger, Donald A. Berry, Anna Barker, John Quackenbush, John L. Marshall, George Poste, Jeffrey L. Vacirca, Gregory A. Vidal, Lee S. Schwartzberg, David D. Halbert, Andreas Voss, Daniel Magee, Mark R. Miglarese, Michael Famulok, Günter Mayer, David Spetzler
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/5a4c54b8e9744dccbcb331d197302fe8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5a4c54b8e9744dccbcb331d197302fe8
record_format	dspace
spelling	oai:doaj.org-article:5a4c54b8e9744dccbcb331d197302fe82021-12-02T15:34:19ZPoly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes10.1038/s41467-018-03631-z2041-1723https://doaj.org/article/5a4c54b8e9744dccbcb331d197302fe82018-03-01T00:00:00Zhttps://doi.org/10.1038/s41467-018-03631-zhttps://doaj.org/toc/2041-1723Patients’ selection is particularly important in cancer treatment. Here the authors present a proof-of-principle methodology that could be potentially important in assisting therapeutic decisions in the treatment of breast cancer patients.Valeriy DomenyukZoran GatalicaRadhika SanthanamXixi WeiAdam StarkPatrick KennedyBrandon ToussaintSymon LevenbergJie WangNianqing XiaoRichard GreilGabriel RinnerthalerSimon P. GampenriederAmy B. HeimbergerDonald A. BerryAnna BarkerJohn QuackenbushJohn L. MarshallGeorge PosteJeffrey L. VacircaGregory A. VidalLee S. SchwartzbergDavid D. HalbertAndreas VossDaniel MageeMark R. MiglareseMichael FamulokGünter MayerDavid SpetzlerNature PortfolioarticleScienceQENNature Communications, Vol 9, Iss 1, Pp 1-9 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Valeriy Domenyuk Zoran Gatalica Radhika Santhanam Xixi Wei Adam Stark Patrick Kennedy Brandon Toussaint Symon Levenberg Jie Wang Nianqing Xiao Richard Greil Gabriel Rinnerthaler Simon P. Gampenrieder Amy B. Heimberger Donald A. Berry Anna Barker John Quackenbush John L. Marshall George Poste Jeffrey L. Vacirca Gregory A. Vidal Lee S. Schwartzberg David D. Halbert Andreas Voss Daniel Magee Mark R. Miglarese Michael Famulok Günter Mayer David Spetzler Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes
description	Patients’ selection is particularly important in cancer treatment. Here the authors present a proof-of-principle methodology that could be potentially important in assisting therapeutic decisions in the treatment of breast cancer patients.
format	article
author	Valeriy Domenyuk Zoran Gatalica Radhika Santhanam Xixi Wei Adam Stark Patrick Kennedy Brandon Toussaint Symon Levenberg Jie Wang Nianqing Xiao Richard Greil Gabriel Rinnerthaler Simon P. Gampenrieder Amy B. Heimberger Donald A. Berry Anna Barker John Quackenbush John L. Marshall George Poste Jeffrey L. Vacirca Gregory A. Vidal Lee S. Schwartzberg David D. Halbert Andreas Voss Daniel Magee Mark R. Miglarese Michael Famulok Günter Mayer David Spetzler
author_facet	Valeriy Domenyuk Zoran Gatalica Radhika Santhanam Xixi Wei Adam Stark Patrick Kennedy Brandon Toussaint Symon Levenberg Jie Wang Nianqing Xiao Richard Greil Gabriel Rinnerthaler Simon P. Gampenrieder Amy B. Heimberger Donald A. Berry Anna Barker John Quackenbush John L. Marshall George Poste Jeffrey L. Vacirca Gregory A. Vidal Lee S. Schwartzberg David D. Halbert Andreas Voss Daniel Magee Mark R. Miglarese Michael Famulok Günter Mayer David Spetzler
author_sort	Valeriy Domenyuk
title	Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes
title_short	Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes
title_full	Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes
title_fullStr	Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes
title_full_unstemmed	Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes
title_sort	poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/5a4c54b8e9744dccbcb331d197302fe8
work_keys_str_mv	AT valeriydomenyuk polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT zorangatalica polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT radhikasanthanam polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT xixiwei polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT adamstark polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT patrickkennedy polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT brandontoussaint polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT symonlevenberg polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT jiewang polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT nianqingxiao polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT richardgreil polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT gabrielrinnerthaler polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT simonpgampenrieder polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT amybheimberger polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT donaldaberry polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT annabarker polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT johnquackenbush polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT johnlmarshall polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT georgeposte polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT jeffreylvacirca polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT gregoryavidal polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT leesschwartzberg polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT daviddhalbert polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT andreasvoss polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT danielmagee polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT markrmiglarese polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT michaelfamulok polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT guntermayer polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes AT davidspetzler polyligandprofilingdifferentiatestrastuzumabtreatedbreastcancerpatientsaccordingtotheiroutcomes
_version_	1718386838041788416

Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes

Ejemplares similares